Peripheral neuropathic pain
Conditions
Interventions
Traditional Stimulation Group:Traditional Transcranial Magnetic Stimulation
Individualized Stimulation Group:Individualized Navigation Transcranial Magnetic Stimulation
Sponsors
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Meets the IASP diagnostic criteria for peripheral neuropathic pain, with a disease duration of >= 3 months; 2.Or neuropathic pain resulting from nociceptive pain (ID PAIN scale score >= 2 points); 3.Aged between 18 and 75 years; 4.An average daily pain VAS score of >30 mm over the past week; 5.Able to complete clinical evaluations, MRI scans, and rTMS treatment as required; 6.No changes in pain control medications within 1 week during baseline assessment; 7.Capable of understanding the nature and purpose of the study, willing to participate, and able to comply with the study protocol requirements, including undergoing MRI examinations, providing blood and fecal samples, and cooperating with related follow-ups;
Exclusion criteria
Exclusion criteria: 1.Contraindications for TMS and MRI (e.g., magnetic materials and implants or the presence of metal fragments or foreign bodies; unhealed acute wounds or surgical incisions; claustrophobia; the presence of any type of vascular stents or clips, or a history of related surgeries; inability to lie supine due to illness, etc.); 2.Suffering from psychiatric disorders, aphasia, or cognitive dysfunction (HAMD-17 > 24, HAMA-14 > 29, MMSE <= 24); 3.Having severe cardiopulmonary dysfunction, extreme frailty, or being unable to sit upright for rehabilitation assessments and treatment; 4.Suffering from other diseases that may interfere with the study results, such as epilepsy or myocardial infarction; 5.Pregnant or lactating women; 6.Currently participating in other clinical studies or receiving treatment with other experimental drugs;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in cytokines and metabolomics;BPI;HAMD?HAMA;Changes in intestinal flora;LANSS;EQ5D-5L;Changes in resting-state functional magnetic resonance imaging before treatment and on the day of treatment completion.;PGIC; | — |
Countries
China
Contacts
Public ContactFeng Zhiying
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed